Disease on EC 3.4.24.42 - atrolysin C
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Arthritis
Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent.
Arthritis
Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis.
Arthritis
Aggrecanase cleavage in juvenile idiopathic arthritis patients is minimally detected in the aggrecan interglobular domain but robust at the aggrecan C-terminus.
Arthritis
Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis.
Arthritis
Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis.
Arthritis
Experimental arthritis: Oral aggrecanase inhibitor may slow postinjury cartilage breakdown.
Arthritis
Interleukin-1 Induction of Aggrecanase Gene Expression in Human Articular Chondrocytes is Mediated by Mitogen-Activated Protein Kinases.
Arthritis
Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage.
Arthritis
Mechanisms of proteoglycan metabolism that lead to cartilage destruction in the pathogenesis of arthritis.
Arthritis
Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study.
Arthritis
TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor.
Arthritis
TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).
Arthritis, Juvenile
Aggrecanase cleavage in juvenile idiopathic arthritis patients is minimally detected in the aggrecan interglobular domain but robust at the aggrecan C-terminus.
Arthritis, Rheumatoid
Expression of a wide range of extracellular matrix molecules in the tendon and trochlea of the human superior oblique muscle.
Carcinoma
Expression and distribution of aggrecanases in human larynx: ADAMTS-5/aggrecanase-2 is the main aggrecanase in laryngeal carcinoma.
Chondrosarcoma
The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1.
Chondrosarcoma
Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions.
Chondrosarcoma
Utilization of a recombinant substrate rAgg1 to study the biochemical properties of aggrecanase in cell culture systems.
Endometrial Neoplasms
The investigation of serum levels of ADAMTS 5 and 8 (the A disintegrin and metalloproteinase with thrombospondin motifs) in the etiology of endometrial cancer.
Infections
Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease.
Intervertebral Disc Degeneration
Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc.
Intervertebral Disc Degeneration
Region-Dependent Aggrecan Degradation Patterns in the Rat Intervertebral Disc Are Affected by Mechanical Loading In Vivo.
Intervertebral Disc Displacement
Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc.
Joint Diseases
Association of serum levels of aggrecan ARGS, NITEGE fragments and radiologic knee osteoarthritis in Tunisian patients.
Joint Diseases
Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments.
Joint Diseases
Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2).
Joint Diseases
Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study.
Joint Diseases
The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis.
Leukemia
Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown.
Lyme Disease
Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease.
Lyme Disease
Lyme disease spirochaetes possess an aggrecan-binding protease with aggrecanase activity.
Melanoma
Application of topologically constrained mini-proteins as ligands, substrates, and inhibitors.
Neoplasms
"Aggrecanase" activity is implicated in tumour necrosis factor alpha mediated cartilage aggrecan breakdown but is not detected by an in vitro assay.
Neoplasms
ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes.
Neoplasms
Effect of intra-articular administration of interleukin 1 receptor antagonist on cartilage repair in temporomandibular joint.
Neoplasms
Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship.
Neoplasms
Elevated expression of hypoxia-inducible factor-2alpha regulated catabolic factors during intervertebral disc degeneration.
Neoplasms
Expression and distribution of aggrecanases in human larynx: ADAMTS-5/aggrecanase-2 is the main aggrecanase in laryngeal carcinoma.
Neoplasms
Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions.
Neoplasms
Interleukin 17 induced nitric oxide suppresses matrix synthesis and protects cartilage from matrix breakdown.
Neoplasms
Oncostatin M in combination with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2.
Neoplasms
The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1.
Neoplasms
The investigation of serum levels of ADAMTS 5 and 8 (the A disintegrin and metalloproteinase with thrombospondin motifs) in the etiology of endometrial cancer.
Neoplasms
Tumor necrosis factor alpha-dependent aggrecan cleavage and release of glycosaminoglycans in the meniscus is mediated by nitrous oxide-independent aggrecanase activity in vitro.
Oligodendroglioma
Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity.
Osteoarthritis
10mM glucosamine prevents activation of proADAMTS5 (aggrecanase-2) in transfected cells by interference with post-translational modification of furin.
Osteoarthritis
A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs.
Osteoarthritis
Animal models of osteoarthritis: lessons learned while seeking the 'Holy Grail'.
Osteoarthritis
Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis.
Osteoarthritis
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation.
Osteoarthritis
CXCL12/CXCR4 Axis Regulates Aggrecanase Activation and Cartilage Degradation in a Post-Traumatic Osteoarthritis Rat Model.
Osteoarthritis
Development of human neutralizing antibody to ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2).
Osteoarthritis
Effect of dehydroepiandrosterone on aggrecanase expression in articular cartilage in a rabbit model of osteoarthritis.
Osteoarthritis
Effects of hexosamines and omega-3/omega-6 fatty acids on pH regulation by interleukin 1-treated isolated bovine articular chondrocytes.
Osteoarthritis
Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis.
Osteoarthritis
Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage.
Osteoarthritis
Knockout of ADAMTS5 does not eliminate cartilage aggrecanase activity but abrogates joint fibrosis and promotes cartilage aggrecan deposition in murine osteoarthritis models.
Osteoarthritis
Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2).
Osteoarthritis
Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.
Osteoarthritis
The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review.
Osteoarthritis
The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis.
Osteoarthritis
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.
Osteoarthritis
Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis.
Osteoarthritis, Knee
The association between changes in synovial fluid levels of ARGS-aggrecan fragments, progression of radiographic osteoarthritis and self-reported outcomes: a cohort study.
Persistent Infection
Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease.
Post-Lyme Disease Syndrome
Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease.
Spondylolisthesis
Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc.
Temporomandibular Joint Disorders
Aggrecanase analysis of synovial fluid of temporomandibular joint disorders.
Temporomandibular Joint Disorders
Expression of matrix metalloproteinases and aggrecanase in the synovial fluids of patients with symptomatic temporomandibular disorders.
html completed